… of a potential anti-tick vaccine that would protect against both Lyme borreliosis (LB) and tick-…
cost-effectiveness of a vaccine with potential combined protection against LB and TBE from …

… to a decrease in immunogenicity. Consequently, researchers … OspA has been extensively
studied as a vaccine component … formation of a multivalent recombinant live vaccine. This is of …

… or non-immunogenic, making adjuvants and booster shots a … vaccine before administration,
the ferritin-OspA platform still shows promise as a protective vaccine against Lyme disease…

… Emphasizing multivalent and combination vaccine strategies and targeting … Borrelia
burgdorferi antigens like OspA or OspC could protect both humans and animals from lyme disease …

… of multivalent aptamers … vaccination against the causative agents of Lyme borreliosis is still
under intense investigation and research mainly targets the outer membrane protein OspA. In …

… (OspA ST) 1–6 by active immunization of individuals aged 5 years of age or older [8] in a
multivalent design to enable assessment of safety and efficacy both in Europe and the US. …

… VLA-15 is a multivalent recombinant vaccine candidate that … A (OspA) of lyme disease
spirochete, Borrelia burgdorferi [149… safety and immunogenicity at different doses of this vaccine …

… for vaccine development against influenza, Epstein-Barr, HIV, hepatitis-C, Lyme disease,
and … is a critical need for vaccines that offer high levels of immunogenicity, safety, and cross-…

… lessen the immunogenicity of the inactivated vaccine [1]. In order to reduce safety concerns
… of antigens on the surface of nanoparticles allows multivalent binding of B-cell receptors thus …

… OspA and OspC were expressed on Neisseria meningitidis OMVs to create a concept antiLyme
disease vaccine. … , N., et al., Safety and immunogenicity of a novel multivalent OspA …